United Therapeutics Corporation
United Therapeutics Corporation (UTHR) Revenue
Annual & quarterly revenue history · segment & region breakdown
UTHR · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsUnited Therapeutics Corporation trailing twelve-month (TTM) revenue is $3.17B, an increase of 10.61% year-over-year from $3.18B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $3.18B | +$0.31B | +10.61% |
| 2024-12-31 | $2.88B | +$0.55B | +23.63% |
| 2023-12-31 | $2.33B | +$0.39B | +20.20% |
| 2022-12-31 | $1.94B | +$0.25B | +14.88% |
| 2021-12-31 | $1.69B | +$0.20B | +13.63% |
| 2020-12-31 | $1.48B | +$0.03B | +2.38% |
| 2019-12-31 | $1.45B | -$0.18B | -11.00% |
| 2018-12-31 | $1.63B | -$0.10B | -5.65% |
| 2017-12-31 | $1.73B | +$0.13B | +7.91% |
| 2016-12-31 | $1.60B | +$0.13B | +9.08% |
Compare revenue vs peers
BiotechnologyCompare UTHR revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income United Therapeutics Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
United Therapeutics Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from United Therapeutics Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
UTHR revenue · 4 questionsUTHR's trailing twelve-month (TTM) revenue is $3.17B. That is an increase of 10.61% year-over-year from $3.18B in FY2025.
▸ Source: FMP · United Therapeutics Corporation SEC filings · GAAP · United Therapeutics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026